Sun Pharmaceutical Industries Ltd. - Research Center
524715 SUNPHARMA Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 18 | Mar ' 17 | Mar ' 16 | Mar ' 15 | Mar ' 14 | |
|---|---|---|---|---|---|
| Sales | 7,947.60 | 7,806.70 | 7,863.69 | 8,017.20 | 2,762.56 |
| Operating profit | 123.02 | 95.27 | -418.67 | -452.02 | 416.75 |
| Interest | 388.31 | 223.56 | 574.10 | 551.25 | 2.56 |
| Gross profit | 862.75 | 386.12 | -547.68 | -898.29 | 517.21 |
| EPS (Rs) | -2.06 | -0.15 | -4.52 | -7.12 | 1.45 |
Annual
results in details
| Mar ' 18 | Mar ' 17 | Mar ' 16 | Mar ' 15 | Mar ' 14 | |
|---|---|---|---|---|---|
| Other income | 1,128.04 | 514.41 | 445.09 | 104.98 | 103.02 |
| Stock adjustment | 159.26 | -162.79 | -14.38 | 318.10 | -14.53 |
| Raw material | 2,167.52 | 2,284.52 | 1,838.31 | 2,261.11 | 894.62 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 1,617.69 | 1,486.17 | 1,476.69 | 1,486.69 | 278.96 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 3,880.11 | 4,103.53 | 4,981.74 | 4,403.32 | 1,186.76 |
| Provisions made | - | - | - | - | - |
| Depreciation | 432.23 | 418.56 | 464.25 | 660.68 | 100.83 |
| Taxation | -25.39 | 2.51 | 5.45 | -84.84 | 115.54 |
| Net profit / loss | -494.59 | -34.95 | -1,087.51 | -1,474.13 | 300.84 |
| Extra ordinary item | -950.50 | - | -70.13 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 239.93 | 239.93 | 240.66 | 207.12 | 207.12 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | 7546.68 | 7528.18 |
| Agg.of non promotoholding (%) | - | - | - | 36.44 | 36.35 |
| OPM (%) | 1.55 | 1.22 | -5.32 | -5.64 | 15.09 |
| GPM (%) | 9.51 | 4.64 | -6.59 | -11.06 | 18.05 |
| NPM (%) | -5.45 | -0.42 | -13.09 | -18.15 | 10.50 |
© 2019 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis